ArticleCase reports in ophthalmology
Nab-Paclitaxel-Induced Cystoid Macular Edema with Minimal Fluorescein Leakage: A Case Report of Two Patients from a Tertiary Referral Center.
Article in Case reports in ophthalmology. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: The aim of the study was to report 2 cases of nab-paclitaxel (nab-PTX)-induced macular edema and describe its incidence over a 5-year period at a tertiary center. Case Presentations: We retrospectively reviewed patients who received nab-PTX between July 2020 and June 2025 across several departments at our institution. Ophthalmic findings, multimodal imaging results, management, and outcomes were analyzed. Among 183 patients treated with nab-PTX, 25 symptomatic patients were referred to ophthalmology, and 2 were adjudicated as definite taxane-induced macular edema (TIME; observed proportion, 2/183; 1.1%). Both patients were men with metastatic pancreatic cancer receiving gemcitabine and nab-PTX. Optical coherence tomography (OCT) demonstrated bilateral cystoid macular edema. In Case 1, fluorescein angiography (FA) showed no macular leakage or vasculitis. Central retinal thickness (CRT) improved from 479/582 µm (right/left) to 175/173 µm after discontinuation of therapy, with macular edema resolving by 11 weeks. In Case 2, FA was not performed because of the patient's poor general condition; OCT angiography showed no microaneurysms or other findings suggestive of alternative causes of macular edema. CRT improved from 659/663 µm to 207/232 µm at 1 month after discontinuation, with complete resolution by 3 months. Best-corrected visual acuity improved in both cases after nab-PTX discontinuation. Conclusion: Nab-PTX can cause bilateral cystoid macular edema, often with minimal or absent FA leakage, and treatment discontinuation can lead to anatomical and functional recovery. Early recognition and prompt interdisciplinary management are important to prevent potentially irreversible visual impairment. Because ophthalmologic evaluation was symptom-driven, asymptomatic, or mildly symptomatic, TIME may have been underdetected; therefore, this observed proportion should not be interpreted as a population-level incidence estimate.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.